美国辛辛那提儿童医院医疗中心Bruce C. Trapnell团队研究了吸入莫拉司亭治疗自身免疫性肺泡蛋白沉着症的疗效。2020年9月7日，《新英格兰医学杂志》在线发表了该成果。
Title: Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
Author: Bruce C. Trapnell, M.D.,, Yoshikazu Inoue, M.D., Ph.D.,, Francesco Bonella, M.D., Ph.D.,, Cliff Morgan, B.M.,, Stéphane Jouneau, M.D., Ph.D.,, Elisabeth Bendstrup, M.D., Ph.D.,, Ilaria Campo, Ph.D.,, Spyros A. Papiris, M.D.,, Etsuro Yamaguchi, M.D., Ph.D.,, Erdogan Cetinkaya, M.D.,, Mikhail M. Ilkovich, M.D.,, Mordechai R. Kramer, M.D.,, Marcel Veltkamp, M.D.,, Michael Kreuter, M.D.,, Tomohisa Baba, M.D.,, Cecilia Ganslandt, M.D.,, Inge Tarnow, D.V.M., Ph.D.,, Grant Waterer, M.B., B.S., Ph.D., M.B.A.,, and Taneli Jouhikainen, M.D., Ph.D., M.B.A.
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia. It is caused by disruption of granulocyte–macrophage colony-stimulating factor (GM-CSF) signaling, which pulmonary alveolar macrophages require to clear surfactant. Recently, inhaled GM-CSF was shown to improve the partial pressure of arterial oxygen in patients with aPAP.
In a double-blind, placebo-controlled, three-group trial, we randomly assigned patients with aPAP to receive the recombinant GM-CSF molgramostim (300 μg once daily by inhalation), either continuously or intermittently (every other week), or matching placebo. The 24-week intervention period was followed by an open-label treatment-extension period. The primary end point was the change from baseline in the alveolar–arterial difference in oxygen concentration (A-aDo2) at week 24.
In total, 138 patients underwent randomization; 46 were assigned to receive continuous molgramostim, 45 to receive intermittent molgramostim, and 47 to receive placebo. Invalid A-aDo2 data for 4 patients (1 in each molgramostim group and 2 in the placebo group) who received nasal oxygen therapy during arterial blood gas measurement were replaced by means of imputation. For the primary end point — the change from baseline in the A-aDo2 at week 24 — improvement was greater among patients receiving continuous molgramostim than among those receiving placebo (12.8 mm Hg vs. 6.6 mm Hg; estimated treatment difference, 6.2 mm Hg; P=0.03 by comparison of least-squares means). Patients receiving continuous molgramostim also had greater improvement than those receiving placebo for secondary end points, including the change from baseline in the St. George’s Respiratory Questionnaire total score at week 24 (12.4 points vs. 5.1 points; estimated treatment difference, 7.4 points; P=0.01 by comparison of least-squares means). For multiple end points, improvement was greater with continuous molgramostim than with intermittent molgramostim. The percentages of patients with adverse events and serious adverse events were similar in the three groups, except for the percentage of patients with chest pain, which was higher in the continuous-molgramostim group.
In patients with aPAP, daily administration of inhaled molgramostim resulted in greater improvements in pulmonary gas transfer and functional health status than placebo, with similar rates of adverse events.